# EDGAR Filing Document

**Accession Number:** 0001840574
**File Stem:** 0001193125-25-165124
**Filing Date:** 2025-7
**Character Count:** 8833
**Document Hash:** 5a7279462baa8155c3068ae370499ecc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-165124.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001193125-25-165124

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250725

**DATE AS OF CHANGE**: 20250725

**EFFECTIVENESS DATE**: 20250725

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verve Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824800132
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-257175
- **FILM NUMBER:** 251150108

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (978) 501-3026

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

**As filed with the Securities and Exchange Commission on July 25, 2025** 

**Registration No. 333-257175** 

**Registration No. 333-263518** 

**Registration No. 333-270207** 

**Registration No. 333-277385** 

**Registration No. 333-285309** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-257175** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263518** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270207** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277385** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285309** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## VERVE THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **82-4800132** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **201 Brookline Avenue, Suite 601**<br> **Boston, Massachusetts** | **02215** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2018 Equity Incentive Plan** 

**2021 Stock Incentive Plan** 

**Amended and Restated 2021 Employee Stock Purchase Plan** 

**2024 Inducement Stock Incentive Plan** 

**(Full titles of the plans)** 

**Jonathan R. Haug** 

**President** 

**Verve Therapeutics, Inc.** 

**Lilly Corporate Center** 

**Indianapolis, Indiana 46285** 

**(Name and address of agent for service)** 

**(317) 276-2000** 

**(Telephone number, including area code, of agent for service)** 

***Copy to:***

**Sophia Hudson, P.C.** 

**Sharon Freiman, P.C.** 

**Kirkland & Ellis LLP** 

**601 Lexington Avenue** 

**New York, New York 10022** 

**Telephone: (212) 446-4800** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (these "<u>Post-Effective Amendments</u>") filed by Verve Therapeutics, Inc. (the "<u>Registrant</u>") relate to the following registration statements on Form S-8 (together, the "<u>Registration Statements</u>"):

1. Registration Statement No. [333-257175](http://www.sec.gov/Archives/edgar/data/1840574/000119312521193289/d150924ds8.htm) , registering an aggregate of 10,321,696 shares of the Registrant's common stock, $0.001 par value
per share (the " <u>Common Stock</u> "), consisting of (i) 5,258,661 shares of Common Stock issuable under the Registrant's 2018 Equity Incentive Plan, (ii) 4,629,719 shares of Common Stock issuable under the Registrant's 2021
Stock Incentive Plan (the " <u>2021 Plan</u> ") and (iii) 433,316 shares of Common Stock issuable under the Registrant's Amended and Restated 2021 Employee Stock Purchase Plan (the " <u>ESPP</u> "), which was filed with the U.S.
Securities and Exchange Commission (the " <u>Commission</u> ") on June 17, 2021;

2. Registration Statement No. [333-263518](http://www.sec.gov/Archives/edgar/data/1840574/000119312522074039/d280049ds8.htm) , registering an aggregate of 2,910,704 shares of Common Stock consisting of (i) 2,425,587 shares of
Common Stock issuable under the 2021 Plan and (ii) 485,117 shares of Common Stock issuable under the ESPP, which was filed with the Commission on March 14, 2022;

3. Registration Statement No. [333-270207](http://www.sec.gov/Archives/edgar/data/1840574/000119312523057300/d462185ds8.htm) , registering an aggregate of 3,703,849 shares of Common Stock consisting of (i) 3,086,541 shares of
Common Stock issuable under the 2021 Plan and (ii) 617,308 shares of Common Stock issuable under the ESPP, which was filed with the Commission on March 2, 2023;

4. Registration Statement No. [333-277385](http://www.sec.gov/Archives/edgar/data/1840574/000119312524047138/d775790ds8.htm) , registering an aggregate of 8,918,182 shares of Common Stock consisting of (i) 4,098,485 shares of
Common Stock issuable under the 2021 Plan, (ii) 819,697 shares of Common Stock issuable under the ESPP and (iii) 4,000,000 shares of Common Stock issuable under the Registrant's 2024 Inducement Stock Incentive Plan, which was filed with the
Commission on February 27, 2024; and

5. Registration Statement No. [333-285309](http://www.sec.gov/Archives/edgar/data/1840574/000119312525037653/d919693ds8.htm) , registering an aggregate of 5,325,493 shares of Common Stock consisting of (i) 4,437,911 shares of
Common Stock issuable under the 2021 Plan and (ii) 887,582 shares of Common Stock issuable under the ESPP, which was filed with the Commission on February 27, 2025.

On July 25, 2025, pursuant to the Agreement and Plan of Merger, dated June 16, 2025 (the "<u>Merger Agreement</u>"), by and among the Registrant, Eli Lilly and Company ("<u>Parent</u>") and Ridgeway Acquisition Corporation ("<u>Purchaser</u>"), Purchaser merged with and into the Registrant (the "<u>Merger</u>"), with the Registrant continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under such Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statements and removes from registration all of the securities that remain unsold under the Registration Statements as of the date hereof, if any.

The Registrant is filing these Post-Effective Amendments to withdraw and remove from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, Indiana, on July 25, 2025.

---

| | |
|:---|:---|
| **VERVE THERAPEUTICS, INC.** | **VERVE THERAPEUTICS, INC.** |
| By: | /s/ Jonathan R. Haug |
| Name: | Jonathan R. Haug |
| Title: | President |

---

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments.